er sessions on Monday,
December 8, 2008.
-- "Safety and Efficacy of the Terminal Complement Inhibitor
Eculizumab in Japanese Patients with Paroxysmal Nocturnal
Hemoglobinuria: AEGIS Phase II Clinical Study Results," Dr. Yuzuru
Kanakura, et al.
-- "Modification of the Eculizumab Dose to Successfully Manage
Intravascular Breakthrough Hemolysis in Patients with Paroxysmal
Nocturnal Hemoglobinuria," Dr. Richard Kelly, et al.
-- "Effect of Reducing Intravascular Hemolysis on Ferritin Homeostasis
in Eculizumab Treated Paroxysmal Nocturnal Hemoglobinuria (PNH)
Patients," Dr. Alexander Roeth, et al.
The following abstracts will be presented in poster sessions on Sunday,
December 7, 2008.
-- "Successful Treatment of Atypical Hemolytic Uremic Syndrome with
the Complement Inhibitor Eculizumab," Jens Nuernberger, et al.
-- "Long-term Efficacy of the Terminal Complement Inhibitor Eculizumab
in a Patient with Cold Agglutinin Disease (CAD)," Dr. Alexander
Roeth, et al.
The following abstract will be presented as an on-
Page: 1 2 3 4 Related medicine news :1
|SOURCE Alexion Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. USC researchers identify key mechanism that regulates the development of stem cells into neurons2
. Cornell researchers study showing evidence of a major environmental trigger for autism3
. Maastricht University researchers produce neural fingerprint of speech recognition4
. Researchers aim to over-stress already taxed mantle cell lymphoma cells5
. Researchers discover new risk factor for cardiovascular disease, and a way to control it6
. First Study of War-Related Mental Disorders Among Iraqis 10 Years Post-Gulf War Published by Researchers at Wayne State University and Basrah University, Iraq7
. Researchers find predictive tests and early treatment delay progression of blood cell cancer8
. Researchers describe how chronic inflammation can lead to stomach cancer9
. Researchers ID Genetic Markers for Esophageal Cancer10
. Researchers identify mechanism, possible drug treatment for tumors in neurofibromatosis11
. Cancer requires support from immune system to develop, UT Southwestern researchers report